Sign in
4

Changes in Ownership

Vanda Pharmaceuticals Inc. Filed Acc 0001209191-13-053649

SVP & Chief Commercial Officer sold 107,500 shares at an average $12.03 ($1,293,277)

  • SVP & Chief Commercial Officer acquired 98,125 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Repella Robert · SVP & Chief Commercial Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2013-11-19 Sale : show line 1 in the form −2,885 $12.07 $34,829 21,490 D
2013-11-20 Exercise or conversion : show line 2 in the form +40,515 $5.90 $239,039 62,005 D
2013-11-20 Sale : show line 3 in the form −40,515 $11.89 $481,659 21,490 D
2013-11-21 Exercise or conversion : show line 4 in the form +23,040 $5.90 $135,936 44,530 D
2013-11-21 Exercise or conversion : show line 5 in the form +34,570 $3.12 $107,858 79,100 D
2013-11-21 Sale : show line 6 in the form −64,100 $12.12 $776,789 15,000 D
Open-market sales · 107,500 sh · avg $12.03 · $1,293,277

Table II: Derivative

3 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2013-11-20 Exercise or conversion : show line 7 in the form Employee Stock Option (Right to Buy) −40,515 $5.90 2021-10-24 40,515 189,485 D
2013-11-21 Exercise or conversion : show line 8 in the form Employee Stock Option (Right to Buy) −23,040 $5.90 2021-10-24 23,040 166,445 D
2013-11-21 Exercise or conversion : show line 9 in the form Employee Stock Option (Right to Buy) −34,570 $3.12 2022-12-06 34,570 21,680 D
Loading xslF345X03/doc4.xml…